# Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients

> **NCT00418574** · PHASE2,PHASE3 · TERMINATED · sponsor: **Menarini Group** · enrollment: 888 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **BIOLOGICAL:** Abagovomab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00418574
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2010-12
- **Final completion:** 2011-06
- **Target enrollment:** 888 (ACTUAL)
- **Why stopped:** No benefit on primary end point (RFS); no rationale to collect survival data
- **Last updated:** 2011-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418574, "Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00418574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*